COVID-19 infection and incident diabetes in American Indian and Alaska Native people: a retrospective cohort study

James W. Keck, Mary E. Lacy, Sara Bressler, Ian Blake, Uzo Chukwuma, Michael G. Bruce

Producción científica: Articlerevisión exhaustiva

1 Cita (Scopus)

Resumen

Background: Evidence suggests an increased risk of new-onset diabetes following COVID-19 infection. American Indian/Alaska Native (AI/AN) people were disparately impacted by the COVID-19 pandemic and historically have had higher diabetes incidence than other racial/ethnic groups in the US. We measured the association between COVID-19 infection and incident diabetes in AI/AN people. Methods: We conducted a retrospective cohort study using de-identified patient data from the Indian Health Service's (IHS) National Patient Information Reporting System. We estimated age-adjusted diabetes incidence rates, incidence rate ratios, and adjusted hazard ratios among three cohorts spanning pre-pandemic (1/1/2018–2/28/2020) and pandemic (3/1/2020–12/31/2021) timeframes: 1) pre-pandemic cohort (1,503,085 individuals); 2) no-COVID-19 pandemic cohort (1,344,339 individuals); and 3) COVID-19 cohort (176,483 individuals). Findings: The COVID-19 cohort had an increased hazard of diabetes compared to the no-COVID-19 group (adjusted hazard ratio (aHR) = 1.56; 95% CI: 1.50–1.62) and the pre-pandemic group (aHR = 1.27; 95% CI: 1.22–1.32). The association between COVID-19 infection and new-onset diabetes was stronger in those with severe COVID-19 illness. A sensitivity analysis comparing the COVID-19 cohort to members of other cohorts that had acute upper respiratory infections showed an attenuated but higher risk of new-onset diabetes in those with COVID-19. Interpretation: AI/AN people diagnosed with COVID-19 had an elevated risk of a new diabetes diagnosis when compared to the no-COVID-19 group and the pre-pandemic group. The increased diabetes risk in the COVID-19 group remained in a sensitivity analysis that limited the comparator groups to individuals with an AURI diagnosis. Funding: US National Institute of Diabetes and Digestive and Kidney Diseases.

Idioma originalEnglish
Número de artículo100727
PublicaciónThe Lancet Regional Health - Americas
Volumen33
DOI
EstadoPublished - may 2024

Nota bibliográfica

Publisher Copyright:
© 2024 The Authors

Financiación

US National Institute of Diabetes and Digestive and Kidney Diseases.This work was supported by the National Institutes of Health (R34-DK132548-01S1). The funder had no role in writing the manuscript or the decision to submit it for publication. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This work was supported by the National Institutes of Health (R34-DK132548-01S1). The funder had no role in writing the manuscript or the decision to submit it for publication. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

FinanciadoresNúmero del financiador
Centers for Disease Control and Prevention
National Institutes of Health (NIH)R34-DK132548-01S1
National Institutes of Health (NIH)

    ASJC Scopus subject areas

    • Internal Medicine
    • Health Policy
    • Public Health, Environmental and Occupational Health

    Huella

    Profundice en los temas de investigación de 'COVID-19 infection and incident diabetes in American Indian and Alaska Native people: a retrospective cohort study'. En conjunto forman una huella única.

    Citar esto